BACKGROUND: We test the hypothesis that in older persons higher plasma levels of inflammatory markers predict the development of depressive symptoms during a 6-year follow-up. METHOD: This study is part of the InCHIANTI (Invecchiare in Chianti, aging in the Chianti area) study, a prospective population-based study of older persons. The sample consisted of 991 participants, ages 65 years and older. Serum levels of C-reactive protein, interleukin (IL)-1beta, IL-1 receptor antagonist (ra), tumor necrosis factor-alpha, IL-6, IL-6 receptor, and IL-18 were measured. Depressive symptoms were assessed at baseline and at the 3- and 6-year follow-ups with the Center for Epidemiological Studies-Depression Scale (CES-D). Depressed mood was defined as CES-D > 20. Potential confounders were baseline variables related to sociodemographic, somatic health, and functional status. RESULTS: At baseline, IL-1ra levels were significantly higher (p = .004) in depressed compared with nondepressed participants. After adjustment for confounders, among subjects free of depression at baseline, those in the third and fourth IL-1ra quartiles compared with those in the lowest quartile had, respectively, a 2.32-fold (95% confidence interval: 1.21-4.42, p = .01) and 2.78-fold (95% confidence interval: 1.47-5.26, p = .002) higher risk of developing depressed mood during a 6-year follow-up. CONCLUSIONS: In old age, persons with high plasma levels of IL1-ra had a higher risk of developing depressive symptoms over time. These findings suggest a potential causal role for inflammation in the development of depressive symptoms in older persons.
BACKGROUND: We test the hypothesis that in older persons higher plasma levels of inflammatory markers predict the development of depressive symptoms during a 6-year follow-up. METHOD: This study is part of the InCHIANTI (Invecchiare in Chianti, aging in the Chianti area) study, a prospective population-based study of older persons. The sample consisted of 991 participants, ages 65 years and older. Serum levels of C-reactive protein, interleukin (IL)-1beta, IL-1 receptor antagonist (ra), tumor necrosis factor-alpha, IL-6, IL-6 receptor, and IL-18 were measured. Depressive symptoms were assessed at baseline and at the 3- and 6-year follow-ups with the Center for Epidemiological Studies-Depression Scale (CES-D). Depressed mood was defined as CES-D > 20. Potential confounders were baseline variables related to sociodemographic, somatic health, and functional status. RESULTS: At baseline, IL-1ra levels were significantly higher (p = .004) in depressed compared with nondepressed participants. After adjustment for confounders, among subjects free of depression at baseline, those in the third and fourth IL-1ra quartiles compared with those in the lowest quartile had, respectively, a 2.32-fold (95% confidence interval: 1.21-4.42, p = .01) and 2.78-fold (95% confidence interval: 1.47-5.26, p = .002) higher risk of developing depressed mood during a 6-year follow-up. CONCLUSIONS: In old age, persons with high plasma levels of IL1-ra had a higher risk of developing depressive symptoms over time. These findings suggest a potential causal role for inflammation in the development of depressive symptoms in older persons.
Authors: Mary A Whooley; Catherine M Caska; Bethany E Hendrickson; Meghan A Rourke; Joseph Ho; Sadia Ali Journal: Biol Psychiatry Date: 2007-04-16 Impact factor: 13.382
Authors: Anita H J van den Biggelaar; Jacobijn Gussekloo; Anton J M de Craen; Marijke Frölich; Max L Stek; Roos C van der Mast; Rudi G J Westendorp Journal: Exp Gerontol Date: 2007-02-04 Impact factor: 4.032
Authors: L Ferrucci; S Bandinelli; E Benvenuti; A Di Iorio; C Macchi; T B Harris; J M Guralnik Journal: J Am Geriatr Soc Date: 2000-12 Impact factor: 5.562
Authors: M A Bremmer; A T F Beekman; D J H Deeg; B W J H Penninx; M G Dik; C E Hack; W J G Hoogendijk Journal: J Affect Disord Date: 2007-08-22 Impact factor: 4.839
Authors: Sarah R Horn; Madison M Long; Benjamin W Nelson; Nicholas B Allen; Philip A Fisher; Michelle L Byrne Journal: Brain Behav Immun Date: 2018-06-19 Impact factor: 7.217
Authors: Yuri Milaneschi; Angelina R Sutin; Antonio Terracciano; Marco Canepa; Kristofer S Gravenstein; Josephine M Egan; Nicole Vogelzangs; Jack M Guralnik; Stefania Bandinelli; Brenda W J H Penninx; Luigi Ferrucci Journal: Psychoneuroendocrinology Date: 2014-01-04 Impact factor: 4.905
Authors: Paula R Sherwood; Thomas J Price; Jason Weimer; Dianxu Ren; Heidi S Donovan; Charles W Given; Barbara A Given; Richard Schulz; Jennifer Prince; Catherine Bender; Florien W Boele; Anna L Marsland Journal: J Neurooncol Date: 2016-02-23 Impact factor: 4.130
Authors: Yuri Milaneschi; Stefania Bandinelli; Brenda W Penninx; Anna Maria Corsi; Fabrizio Lauretani; Rosamaria Vazzana; Richard D Semba; Jack M Guralnik; Luigi Ferrucci Journal: World J Biol Psychiatry Date: 2011-09-20 Impact factor: 4.132